Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Pierluigi Di Sebastiano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9386-8241; OpenAlex author ID A5028617483. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
96
Papers, trials and grants by year

2012: 6 papers · 2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 20

  1. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  2. Editorial: Exploring microbial interactions in pancreatic ductal adenocarcinoma microenvironment. First author DOI 10.3389/fonc.2025.1725126↗
  3. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  4. High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results f… Co-author DOI 10.3390/cancers14194748↗
  5. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-019-5616-2↗
  6. Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. Co-author DOI 10.1186/s13046-019-1308-7↗
  7. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells. Co-author DOI 10.1186/s13046-018-0904-2↗
  8. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy. Co-author DOI 10.1007/s13304-016-0392-x↗
  9. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  10. BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Co-author DOI 10.1038/ncomms9695↗
  11. SIRT1 and circadian gene expression in pancreatic ductal adenocarcinoma: Effect of starvation. Co-author DOI 10.3109/07420528.2014.1003351↗
  12. A tumour score with multidetector spiral CT for venous infiltration in pancreatic cancer: influence on borderline resectable. Co-author DOI 10.1007/s11547-013-0349-9↗
  13. Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clini… Co-author DOI 10.1186/s12967-014-0248-4↗
  14. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.1016/j.dld.2012.09.014↗
  15. Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. Co-author DOI 10.1016/j.ajpath.2012.07.016↗
  16. Cathepsins and pancreatic cancer: the 2012 update. Co-author DOI 10.1016/j.pan.2012.07.011↗
  17. Correlations among PPARγ, DNMT1, and DNMT3B Expression Levels and Pancreatic Cancer. Last author DOI 10.1155/2012/461784↗
  18. Time-Qualified Patterns of Variation of PPARγ, DNMT1, and DNMT3B Expression in Pancreatic Cancer Cell Lines. Co-author DOI 10.1155/2012/890875↗
  19. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Last author DOI 10.1245/s10434-011-2110-8↗
  20. Combined modality treatments in pancreatic cancer. Co-author DOI 10.1517/14728222.2012.662959↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Serena Veschi · 3 shared papers, 2018–2025 · strength 0.61
  2. Fabio F. di Mola · 9 shared papers, 2012–2022 · strength 0.44
  3. Gabriella Mincione · 1 shared paper, 2025 · strength 0.42
  4. Francesca Tavano · 9 shared papers, 2012–2019 · strength 0.36
  5. Alessandro Cama · 3 shared papers, 2018–2022 · strength 0.29
  6. Angelo Andriulli · 6 shared papers, 2012–2015 · strength 0.19
  7. Nicola Tinari · 2 shared papers, 2018–2022 · strength 0.19
  8. Rosalba Florio · 2 shared papers, 2018–2022 · strength 0.19
  9. Laura De Lellis · 2 shared papers, 2018–2022 · strength 0.19
  10. Paola Lanuti · 2 shared papers, 2018–2022 · strength 0.19
  11. Andrea Fontana · 5 shared papers, 2012–2015 · strength 0.17
  12. Vincenzo De Laurenzi · 3 shared papers, 2012–2019 · strength 0.14
  13. Valerio Pazienza · 4 shared papers, 2012–2015 · strength 0.14
  14. Davide Brocco · 1 shared paper, 2022 · strength 0.11
  15. Lucia Lombardi · 3 shared papers, 2012–2015 · strength 0.11
  16. Maria Cristina Curia · 1 shared paper, 2019 · strength 0.10
  17. Raffaele Pezzilli · 3 shared papers, 2012–2016 · strength 0.09
  18. Aldo Scarpa Scarpa · 3 shared papers, 2012–2016 · strength 0.09
  19. Yulia Y. Maxuitenko · 1 shared paper, 2019 · strength 0.08
  20. Adam B. Keeton · 1 shared paper, 2019 · strength 0.08
  21. Alice Domenichini · 1 shared paper, 2019 · strength 0.08
  22. Aleksandra Adamska · 1 shared paper, 2019 · strength 0.08
  23. Verena Damiani · 1 shared paper, 2019 · strength 0.08
  24. Gary Anthony Piazza · 1 shared paper, 2019 · strength 0.08
  25. Marco Falasca · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.